Do analysts recommend BEAT or NVNO?

HeartBeam presently has a consensus target price of $4.00, suggesting a potential upside of 834.36%. Given HeartBeam's stronger consensus rating and higher probable upside, research analysts clearly believe HeartBeam is more favorable than enVVeno Medical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score HeartBeam 1 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.67 enVVeno Medical 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33

Which has higher valuation & earnings, BEAT or NVNO?

HeartBeam is trading at a lower price-to-earnings ratio than enVVeno Medical, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio HeartBeam N/A N/A -$21.01M -$0.51 N/A enVVeno Medical N/A N/A -$19.47M -$19.33 N/A

Is BEAT or NVNO more profitable?

enVVeno Medical's return on equity of -62.28% beat HeartBeam's return on equity. Company Net Margins Return on Equity Return on Assets HeartBeam N/A -686.78% -348.65% enVVeno Medical N/A -62.28% -56.83%

Do analysts rate PETV or NVNO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PetVivo 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 enVVeno Medical 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33

Is PETV or NVNO more profitable?

enVVeno Medical has a net margin of 0.00% compared to PetVivo's net margin of -902.82%. enVVeno Medical's return on equity of -62.28% beat PetVivo's return on equity. Company Net Margins Return on Equity Return on Assets PetVivo -902.82% -4,813.07% -281.78% enVVeno Medical N/A -62.28% -56.83%

Do analysts prefer FEMY or NVNO?

Femasys presently has a consensus target price of $50.00, indicating a potential upside of 1,591.47%. Given Femasys' stronger consensus rating and higher possible upside, equities analysts plainly believe Femasys is more favorable than enVVeno Medical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Femasys 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 enVVeno Medical 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33

Is FEMY or NVNO more profitable?

enVVeno Medical has a net margin of 0.00% compared to Femasys' net margin of -534.36%. enVVeno Medical's return on equity of -62.28% beat Femasys' return on equity. Company Net Margins Return on Equity Return on Assets Femasys -534.36% -225.97% -74.68% enVVeno Medical N/A -62.28% -56.83%

Do analysts recommend CTSO or NVNO?

Cytosorbents currently has a consensus price target of $5.38, indicating a potential upside of 1,436.15%. Given Cytosorbents' higher possible upside, equities analysts plainly believe Cytosorbents is more favorable than enVVeno Medical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cytosorbents 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 enVVeno Medical 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33

Do analysts recommend NVNO or LFWD?

Lifeward has a consensus price target of $10.00, indicating a potential upside of 41.34%. Given Lifeward's higher probable upside, analysts clearly believe Lifeward is more favorable than enVVeno Medical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score enVVeno Medical 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33 Lifeward 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Is NVNO or LFWD more profitable?

enVVeno Medical has a net margin of 0.00% compared to Lifeward's net margin of -141.28%. enVVeno Medical's return on equity of -62.28% beat Lifeward's return on equity. Company Net Margins Return on Equity Return on Assets enVVeno Medical N/A -62.28% -56.83% Lifeward -141.28% -235.86% -81.72%

enVVeno Medical (NVNO) Competitors

$11.55 +0.45 (+4.05%)

As of 03:56 PM Eastern

Compare

NVNO vs. BEAT, PETV, FEMY, CTSO, and LFWD

Should you buy enVVeno Medical stock or one of its competitors? enVVeno Medical's main competitors and comparable companies include HeartBeam (BEAT), PetVivo (PETV), Femasys (FEMY), Cytosorbents (CTSO), and Lifeward (LFWD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does enVVeno Medical compare to HeartBeam?

HeartBeam (NASDAQ:BEAT) and enVVeno Medical (NASDAQ:NVNO) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, media sentiment, valuation, risk, analyst recommendations and dividends.

enVVeno Medical's return on equity of -62.28% beat HeartBeam's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HeartBeam	N/A	-686.78%	-348.65%
enVVeno Medical	N/A	-62.28%	-56.83%

HeartBeam presently has a consensus target price of $4.00, suggesting a potential upside of 834.36%. Given HeartBeam's stronger consensus rating and higher probable upside, research analysts clearly believe HeartBeam is more favorable than enVVeno Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HeartBeam	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.67
enVVeno Medical	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33

In the previous week, HeartBeam's average media sentiment score of 0.00 equaled enVVeno Medical'saverage media sentiment score.

Company	Overall Sentiment
HeartBeam	Neutral
enVVeno Medical	Neutral

7.8% of HeartBeam shares are held by institutional investors. Comparatively, 34.7% of enVVeno Medical shares are held by institutional investors. 18.0% of HeartBeam shares are held by company insiders. Comparatively, 15.0% of enVVeno Medical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

HeartBeam has a beta of -0.8, indicating that its share price is 180% less volatile than the broader market. Comparatively, enVVeno Medical has a beta of 1.06, indicating that its share price is 6% more volatile than the broader market.

HeartBeam is trading at a lower price-to-earnings ratio than enVVeno Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HeartBeam	N/A	N/A	-$21.01M	-$0.51	N/A
enVVeno Medical	N/A	N/A	-$19.47M	-$19.33	N/A

Summary

enVVeno Medical beats HeartBeam on 6 of the 11 factors compared between the two stocks.

How does enVVeno Medical compare to PetVivo?

PetVivo (NASDAQ:PETV) and enVVeno Medical (NASDAQ:NVNO) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, profitability, analyst recommendations, earnings, dividends, risk and media sentiment.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PetVivo	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
enVVeno Medical	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33

PetVivo has higher revenue and earnings than enVVeno Medical. PetVivo is trading at a lower price-to-earnings ratio than enVVeno Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PetVivo	$1.05M	24.67	-$10.95M	-$0.34	N/A
enVVeno Medical	N/A	N/A	-$19.47M	-$19.33	N/A

24.5% of PetVivo shares are held by institutional investors. Comparatively, 34.7% of enVVeno Medical shares are held by institutional investors. 10.8% of PetVivo shares are held by insiders. Comparatively, 15.0% of enVVeno Medical shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

PetVivo has a beta of 1.36, suggesting that its stock price is 36% more volatile than the broader market. Comparatively, enVVeno Medical has a beta of 1.06, suggesting that its stock price is 6% more volatile than the broader market.

enVVeno Medical has a net margin of 0.00% compared to PetVivo's net margin of -902.82%. enVVeno Medical's return on equity of -62.28% beat PetVivo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PetVivo	-902.82%	-4,813.07%	-281.78%
enVVeno Medical	N/A	-62.28%	-56.83%

In the previous week, PetVivo had 1 more articles in the media than enVVeno Medical. MarketBeat recorded 1 mentions for PetVivo and 0 mentions for enVVeno Medical. PetVivo's average media sentiment score of 0.00 equaled enVVeno Medical'saverage media sentiment score.

Company	Overall Sentiment
PetVivo	Neutral
enVVeno Medical	Neutral

Summary

enVVeno Medical beats PetVivo on 8 of the 13 factors compared between the two stocks.

How does enVVeno Medical compare to Femasys?

Femasys (NASDAQ:FEMY) and enVVeno Medical (NASDAQ:NVNO) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, analyst recommendations, institutional ownership, risk, profitability and dividends.

In the previous week, Femasys' average media sentiment score of 0.00 equaled enVVeno Medical'saverage media sentiment score.

Company	Overall Sentiment
Femasys	Neutral
enVVeno Medical	Neutral

65.3% of Femasys shares are owned by institutional investors. Comparatively, 34.7% of enVVeno Medical shares are owned by institutional investors. 7.8% of Femasys shares are owned by insiders. Comparatively, 15.0% of enVVeno Medical shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Femasys has higher revenue and earnings than enVVeno Medical. Femasys is trading at a lower price-to-earnings ratio than enVVeno Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Femasys	$2.29M	10.82	-$18.63M	-$3.53	N/A
enVVeno Medical	N/A	N/A	-$19.47M	-$19.33	N/A

Femasys has a beta of -2.07, meaning that its share price is 307% less volatile than the broader market. Comparatively, enVVeno Medical has a beta of 1.06, meaning that its share price is 6% more volatile than the broader market.

enVVeno Medical has a net margin of 0.00% compared to Femasys' net margin of -534.36%. enVVeno Medical's return on equity of -62.28% beat Femasys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Femasys	-534.36%	-225.97%	-74.68%
enVVeno Medical	N/A	-62.28%	-56.83%

Femasys presently has a consensus target price of $50.00, indicating a potential upside of 1,591.47%. Given Femasys' stronger consensus rating and higher possible upside, equities analysts plainly believe Femasys is more favorable than enVVeno Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Femasys	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
enVVeno Medical	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33

Summary

Femasys and enVVeno Medical tied by winning 7 of the 14 factors compared between the two stocks.

How does enVVeno Medical compare to Cytosorbents?

Cytosorbents (NASDAQ:CTSO) and enVVeno Medical (NASDAQ:NVNO) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, media sentiment, institutional ownership, earnings, dividends and profitability.

enVVeno Medical has a net margin of 0.00% compared to Cytosorbents' net margin of -48.94%. enVVeno Medical's return on equity of -62.28% beat Cytosorbents' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytosorbents	-48.94%	-431.65%	-41.94%
enVVeno Medical	N/A	-62.28%	-56.83%

In the previous week, Cytosorbents had 6 more articles in the media than enVVeno Medical. MarketBeat recorded 6 mentions for Cytosorbents and 0 mentions for enVVeno Medical. enVVeno Medical's average media sentiment score of 0.00 beat Cytosorbents' score of -0.10 indicating that enVVeno Medical is being referred to more favorably in the news media.

Company	Overall Sentiment
Cytosorbents	Neutral
enVVeno Medical	Neutral

Cytosorbents has higher revenue and earnings than enVVeno Medical. Cytosorbents is trading at a lower price-to-earnings ratio than enVVeno Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytosorbents	$37.06M	0.59	-$8.20M	-$0.29	N/A
enVVeno Medical	N/A	N/A	-$19.47M	-$19.33	N/A

32.9% of Cytosorbents shares are held by institutional investors. Comparatively, 34.7% of enVVeno Medical shares are held by institutional investors. 7.8% of Cytosorbents shares are held by company insiders. Comparatively, 15.0% of enVVeno Medical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Cytosorbents currently has a consensus price target of $5.38, indicating a potential upside of 1,436.15%. Given Cytosorbents' higher possible upside, equities analysts plainly believe Cytosorbents is more favorable than enVVeno Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytosorbents	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
enVVeno Medical	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33

Cytosorbents has a beta of 1.34, indicating that its stock price is 34% more volatile than the broader market. Comparatively, enVVeno Medical has a beta of 1.06, indicating that its stock price is 6% more volatile than the broader market.

Summary

Cytosorbents and enVVeno Medical tied by winning 8 of the 16 factors compared between the two stocks.

How does enVVeno Medical compare to Lifeward?

enVVeno Medical (NASDAQ:NVNO) and Lifeward (NASDAQ:LFWD) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, media sentiment, earnings, dividends and analyst recommendations.

In the previous week, Lifeward had 4 more articles in the media than enVVeno Medical. MarketBeat recorded 4 mentions for Lifeward and 0 mentions for enVVeno Medical. Lifeward's average media sentiment score of 0.10 beat enVVeno Medical's score of 0.00 indicating that Lifeward is being referred to more favorably in the news media.

Company	Overall Sentiment
enVVeno Medical	Neutral
Lifeward	Neutral

enVVeno Medical has a net margin of 0.00% compared to Lifeward's net margin of -141.28%. enVVeno Medical's return on equity of -62.28% beat Lifeward's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
enVVeno Medical	N/A	-62.28%	-56.83%
Lifeward	-141.28%	-235.86%	-81.72%

enVVeno Medical has higher earnings, but lower revenue than Lifeward. enVVeno Medical is trading at a lower price-to-earnings ratio than Lifeward, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
enVVeno Medical	N/A	N/A	-$19.47M	-$19.33	N/A
Lifeward	$22.03M	0.91	-$19.91M	-$16.82	N/A

Lifeward has a consensus price target of $10.00, indicating a potential upside of 41.34%. Given Lifeward's higher probable upside, analysts clearly believe Lifeward is more favorable than enVVeno Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
enVVeno Medical	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
Lifeward	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

34.7% of enVVeno Medical shares are owned by institutional investors. Comparatively, 26.8% of Lifeward shares are owned by institutional investors. 15.0% of enVVeno Medical shares are owned by company insiders. Comparatively, 1.5% of Lifeward shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

enVVeno Medical has a beta of 1.06, suggesting that its stock price is 6% more volatile than the broader market. Comparatively, Lifeward has a beta of 0.39, suggesting that its stock price is 61% less volatile than the broader market.

Summary

enVVeno Medical beats Lifeward on 9 of the 16 factors compared between the two stocks.

Get enVVeno Medical News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NVNO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NVNO vs. The Competition

Export

Metric	enVVeno Medical	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$7.97M	$5.59B	$7.17B	$12.89B
Dividend Yield	N/A	1.76%	2.53%	8.57%
P/E Ratio	-0.60	25.83	273.00	25.40
Price / Sales	N/A	72.35	618.40	98.88
Price / Cash	N/A	33.14	77.82	52.27
Price / Book	0.39	6.06	12.86	6.17
Net Income	-$19.47M	$149.47M	$3.47B	$349.50M
7 Day Performance	7.43%	-1.29%	1.27%	-0.05%
1 Month Performance	3.58%	1.34%	5.84%	0.80%
1 Year Performance	-58.17%	10.30%	25.77%	15.58%

enVVeno Medical Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NVNO enVVeno Medical	1.381 of 5 stars	$11.55 +4.0%	N/A	-59.6%	$7.97M	N/A	N/A	30
BEAT HeartBeam	1.8186 of 5 stars	$0.48 -4.3%	$4.00 +730.9%	-70.2%	$28.34M	N/A	N/A	1,700
PETV PetVivo	N/A	$0.68 flat	N/A	-15.5%	$25.81M	$1.05M	N/A	20	News Coverage Gap Down
FEMY Femasys	2.9204 of 5 stars	$2.92 +2.5%	$50.00 +1,612.3%	-58.6%	$23.87M	$2.29M	N/A	30
CTSO Cytosorbents	2.1021 of 5 stars	$0.36 +1.3%	$5.38 +1,393.1%	-64.3%	$22.33M	$37.06M	N/A	220	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NVNO) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

enVVeno Medical (NVNO) Competitors

NVNO vs. BEAT, PETV, FEMY, CTSO, and LFWD

How does enVVeno Medical compare to HeartBeam?

Summary

How does enVVeno Medical compare to PetVivo?

Summary

How does enVVeno Medical compare to Femasys?

Summary

How does enVVeno Medical compare to Cytosorbents?

Summary

How does enVVeno Medical compare to Lifeward?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NVNO vs. The Competition

enVVeno Medical Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

enVVeno Medical (NVNO) Competitors

NVNO vs. BEAT, PETV, FEMY, CTSO, and LFWD

How does enVVeno Medical compare to HeartBeam?

Is BEAT or NVNO more profitable?

Do analysts recommend BEAT or NVNO?

Does the media favor BEAT or NVNO?

Do insiders & institutionals have more ownership in BEAT or NVNO?

Which has more volatility and risk, BEAT or NVNO?

Which has higher valuation & earnings, BEAT or NVNO?

Summary

How does enVVeno Medical compare to PetVivo?

Do analysts rate PETV or NVNO?

Which has better valuation and earnings, PETV or NVNO?

Do insiders and institutionals have more ownership in PETV or NVNO?

Which has more volatility and risk, PETV or NVNO?

Is PETV or NVNO more profitable?

Does the media favor PETV or NVNO?

Summary

How does enVVeno Medical compare to Femasys?

Does the media prefer FEMY or NVNO?

Do insiders & institutionals have more ownership in FEMY or NVNO?

Which has higher earnings and valuation, FEMY or NVNO?

Which has more volatility and risk, FEMY or NVNO?

Is FEMY or NVNO more profitable?

Do analysts prefer FEMY or NVNO?

Summary

How does enVVeno Medical compare to Cytosorbents?

Is CTSO or NVNO more profitable?

Does the media prefer CTSO or NVNO?

Which has higher valuation & earnings, CTSO or NVNO?

Do insiders and institutionals believe in CTSO or NVNO?

Do analysts recommend CTSO or NVNO?

Which has more risk and volatility, CTSO or NVNO?

Summary

How does enVVeno Medical compare to Lifeward?

Does the media refer more to NVNO or LFWD?

Is NVNO or LFWD more profitable?

Which has higher earnings and valuation, NVNO or LFWD?

Do analysts recommend NVNO or LFWD?

Do institutionals and insiders believe in NVNO or LFWD?

Which has more volatility & risk, NVNO or LFWD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NVNO vs. The Competition

enVVeno Medical Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools